

CITATION REPORT

List of articles citing

Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?

DOI: 10.18632/oncotarget.5580

Oncotarget, 2015, 6, 33944-51.

Source: <https://exaly.com/paper-pdf/61128689/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
52	Dasatinib improves insulin sensitivity and affects lipid metabolism in a patient with chronic myeloid leukaemia. <i>BMJ Case Reports</i> , 2016 , 2016,	0.9	7
51	The Cancer Drug Dasatinib Increases PGC-1 α in Adipose Tissue but Has Adverse Effects on Glucose Tolerance in Obese Mice. <i>Endocrinology</i> , 2016 , 157, 4184-4191	4.8	1
50	Chronic myeloid leukemia: Second-line drugs of choice. <i>American Journal of Hematology</i> , 2016 , 91, 67-75	7.1	24
49	The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic state. <i>Thrombosis Research</i> , 2016 , 145, 54-64	8.2	42
48	Telocytes. <i>Advances in Experimental Medicine and Biology</i> , 2016 ,	3.6	5
47	Electrophysiological Features of Telocytes. <i>Advances in Experimental Medicine and Biology</i> , 2016 , 913, 287-302	3.6	5
46	Tyrosine kinase inhibitors under investigation for the treatment of type II diabetes. <i>Expert Opinion on Investigational Drugs</i> , 2016 , 25, 287-96	5.9	15
45	The value of open access and a patient centric approach to oral oncolytic utilization in the treatment of Chronic Myelogenous Leukemia: A U.S. perspective. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017 , 17, 133-140	2.2	1
44	Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment. <i>Cancer Biomarkers</i> , 2017 , 21, 41-53	3.8	2
43	Genetic risk of prediabetes and diabetes development in chronic myeloid leukemia patients treated with nilotinib. <i>Experimental Hematology</i> , 2017 , 55, 71-75	3.1	1
42	[Leg ulcers occurring under tyrosine kinase inhibitor therapy (sunitinib, nilotinib)]. <i>Annales De Dermatologie Et De Venereologie</i> , 2017 , 144, 49-54	0.3	2
41	The anti-leukemic and lipid lowering effects of imatinib are not hindered by statins in CML: a retrospective clinical study and in vitro assessment of lipid-genes transcription. <i>Leukemia and Lymphoma</i> , 2017 , 58, 1172-1177	1.9	3
40	BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?. <i>TH Open</i> , 2018 , 2, e68-e88	2.7	12
39	Chronic myeloid leukaemia and tyrosine kinase inhibitor therapy: assessment and management of cardiovascular risk factors. <i>Internal Medicine Journal</i> , 2018 , 48 Suppl 2, 5-13	1.6	20
38	Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing. <i>Blood Reviews</i> , 2018 , 32, 289-299	11.1	48
37	Incidence of type 2 diabetes mellitus and hyperlipidemia in patients prescribed dasatinib or nilotinib as first- or second-line therapy for chronic myelogenous leukemia in the US. <i>Current Medical Research and Opinion</i> , 2018 , 34, 353-360	2.5	16
36	Chronic Myeloproliferative Neoplasms: Some Remaining Challenges. <i>HemaSphere</i> , 2018 , 2, e147	0.3	

35	Effect of imatinib on plasma glucose concentration in subjects with chronic myeloid leukemia and gastrointestinal stromal tumor. <i>BMC Endocrine Disorders</i> , 2018 , 18, 77	3.3	9
34	Expert opinion on the metabolic complications of new anticancer therapies: Tyrosine kinase inhibitors. <i>Annales DiEndocrinologie</i> , 2018 , 79, 574-582	1.7	13
33	Precision immunotherapy, mutational landscape, and emerging tools to optimize clinical outcomes in patients with classical myeloproliferative neoplasms. <i>Hematological Oncology</i> , 2018 , 36, 740-748	1.3	2
32	Sulfonamide inhibitors: a patent review 2013-present. <i>Expert Opinion on Therapeutic Patents</i> , 2018 , 28, 541-549	6.8	76
31	Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety. <i>Frontiers in Oncology</i> , 2019 , 9, 603	5.3	46
30	Pharmacovigilance evaluation of the relationship between impaired glucose metabolism and BCR-ABL inhibitor use by using an adverse drug event reporting database. <i>Cancer Medicine</i> , 2019 , 8, 1744-1811	4.8	10
29	Il ruolo dell'Endocrinologo nella gestione dei pazienti trattati per leucemia mieloide cronica. <i>L'Endocrinologo</i> , 2019 , 20, 27-29	0	
28	Full Issue PDF. <i>JACC: CardioOncology</i> , 2019 , 1, I-CXCII	3.8	
27	Adverse effects of dasatinib on glucose-lipid metabolism in patients with chronic myeloid leukaemia in the chronic phase. <i>Scientific Reports</i> , 2019 , 9, 17601	4.9	3
26	Nilotinib in the treatment of chronic myeloid leukemia. <i>Future Oncology</i> , 2019 , 15, 953-965	3.6	19
25	From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview. <i>Antioxidants and Redox Signaling</i> , 2019 , 30, 2110-2153	8.4	73
24	Suitability of APINCH high-risk medications use in diabetes mellitus. <i>European Journal of Pharmacology</i> , 2020 , 867, 172845	5.3	2
23	Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Societ�Italiana Farmacologia (SIF) multidisciplinary consensus position paper. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 154, 103066	7	2
22	How to manage CML patients with comorbidities. <i>Blood</i> , 2020 , 136, 2507-2512	2.2	6
21	How to manage CML patients with comorbidities. <i>Hematology American Society of Hematology Education Program</i> , 2020 , 2020, 237-242	3.1	3
20	Effects of ibrutinib on glucose-lipid metabolism in patients with chronic lymphocytic leukemia (CLL). <i>Leukemia and Lymphoma</i> , 2020 , 61, 2778-2780	1.9	1
19	Effects of proprotein convertase subtilisin/kexin type 9 and nilotinib plasma concentrations on nilotinib-induced hypercholesterolaemia in patients with chronic myeloid leukaemia. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021 , 46, 382-387	2.2	0
18	Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies. <i>Expert Review of Clinical Pharmacology</i> , 2021 , 14, 445-456	3.8	2

17	LMO7 as an Unrecognized Factor Promoting Pancreatic Cancer Progression and Metastasis. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 647387	5.7	3
16	Tyrosine Kinase Inhibitors and Vascular Adverse Events in Patients with Chronic Myeloid Leukemia: A Population-Based, Propensity Score-Matched Cohort Study. <i>Oncologist</i> , 2021 , 26, 974-982	5.7	2
15	Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib. <i>Annals of Hematology</i> , 2021 , 100, 2005-2014	3	3
14	Tyrosine kinase inhibitors and mesenchymal stromal cells: effects on self-renewal, commitment and functions. <i>Oncotarget</i> , 2017 , 8, 5540-5565	3.3	13
13	Adaptive metabolic rewiring to chronic SFK inhibition. <i>Oncotarget</i> , 2017 , 8, 66758-66768	3.3	3
12	Effect of tyrosine kinase inhibitors on the glucose levels in diabetic and nondiabetic patients. <i>Indian Journal of Cancer</i> , 2017 , 54, 136-143	0.9	2
11	Cardiometabolic consequences of targeted anticancer therapies. <i>Journal of Cardiovascular Pharmacology</i> , 2021 ,	3.1	0
10	Cardiovascular Toxicity of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia. <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2018 , 11, 378-387	0.3	2
9	OCT-Based Management of Nilotinib-Associated CAD in a Patient With Chronic Myeloid Leukemia. <i>JACC: CardioOncology</i> , 2019 , 1, 318-321	3.8	1
8	Nilotinib-Induced Diabetes Mellitus in a Young Female with Chronic Myeloid Leukemia. <i>Cureus</i> , 2020 , 12, e10277	1.2	1
7	Lifelong TKI therapy: how to manage cardiovascular and other risks. <i>Hematology American Society of Hematology Education Program</i> , 2021 , 2021, 113-121	3.1	1
6	Alterations in cellular metabolisms after Imatinib therapy: a review.. <i>Medical Oncology</i> , 2022 , 39, 95	3.7	0
5	Cancer therapy's impact on lipid metabolism: Mechanisms and future avenues. 9,		0
4	Role of B Lymphocytes in the Pathogenesis of NAFLD: A 2022 Update. 2022 , 23, 12376		1
3	A practical guide to managing hypertension, hyperlipidemia, and hyperglycemia in patients with chronic myeloid leukemia. 9,		0
2	Alterations in cellular metabolisms after TKI therapy for Philadelphia chromosome-positive leukemia in children: A review. 12,		0
1	Impact of tyrosine kinase inhibitors on glucose control and insulin regulation in chronic myeloid leukemia patients.		0